Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

MMRF teams-up with Onyx to advance personalized multiple myeloma therapy

Home/Research, Supplements/Drugs/MMRF teams-up with Onyx to advance personalized multiple myeloma therapy

MMRF teams-up with Onyx to advance personalized multiple myeloma therapy

This news is vitally important to a number of us who have been pushing for more individualized therapy regimens and dosing:

Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals Announce Multi-Year Collaboration to Accelerate Personalized Medicine Approaches for Multiple Myeloma

– Onyx joins growing consortium of partners helping to advance the next generation of targeted therapies – 

NORWALK, Conn. and SOUTH SAN FRANCISCO, Calif., Dec. 14, 2011 /PRNewswire/ — The Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the start of a multi-year collaboration in support of the comprehensive research initiative in personalized medicine sponsored by the MMRF. The MMRF’s Personalized Medicine Initiative, the largest research effort ever undertaken against this incurable disease, is designed to enable the molecular characterization of patients with multiple myeloma and advance the development of new, targeted treatments for the disease.

As a charter member of a growing pre-competitive consortium which includes academic, industry and non-profit members, Onyx, which has a focus in multiple myeloma, will provide scientific and financial support for this comprehensive research initiative. The pre-competitive component of the collaboration gives the consortium equal access to data generated for a set period of time before the data is released in the public domain.

“We look forward to working closely with Onyx to gain a much better understanding of how this disease develops and progresses, and to bring the entire R&D ecosystem together to greatly accelerate the development of new treatments, and ultimately, a cure,” said Kathy Giusti, founder and CEO of the MMRF and Multiple Myeloma Research Consortium, and a multiple myeloma patient. “Onyx is an invaluable partner who shares our passion for rapidly translating new insights into breakthrough therapies to bring us closer to a cure. We look forward to working together in this critical initiative.”

The MMRF announced earlier this year that enrollment has begun in its CoMMpass(SM) Study (relating Clinical Outcomes in Multiple Myeloma to Personal AsseSSment of genetic profile), the cornerstone of the multiple myeloma personalized medicine research effort. This landmark 1000-patient longitudinal study will provide unprecedented insights into the molecular course of a patient’s disease, from initial diagnosis through their response to treatment. As consortium members, Onyx and other industry partners will have early access to the data that emerge from this study, potentially providing them with new targets for intervention and biomarker development, accelerating the time from discovery to clinical development.

“There is a significant need for new treatment options in multiple myeloma, and we are proud to work in partnership with MMRF, researchers and others in the industry to better understand the disease at a molecular level and potentially develop targeted therapies that will improve the lives of these patients,” said N. Anthony Coles, M.D., president and CEO, Onyx.

“We share the MMRF’s vision that to succeed we will not only need great science, but also the creation of innovative models for collaboration to accelerate rapid development of promising treatments.”

I will keep you updated about this in the upcoming weeks.  Maybe I can set-up an interview with MMRF/Onyx officials to help us learn more.

Feel good and keep smiling!  Pat